Summary of Study ST001795
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001139. The data can be accessed directly via it's Project DOI: 10.21228/M8GH59 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST001795 |
| Study Title | Changes in mesenteric lymph lipid profile of mice upon high-fat diet with and without Celecoxib (part I) |
| Study Type | Untargeted lipidomics analysis |
| Study Summary | Untargeted lipid profiling of mesenteric mice lymph from mice fed with CHOW, HFD and HFD supplemented with COx-2 inhibitor drug Celecoxib. It is proposed that Celecoxib can protect from deleterious morphological changes in lymphatic system caused by obesity/HFD. |
| Institute | Monash Institute of Pharmaceutical Sciences |
| Department | Drug Delivery, Disposition and Dynamics |
| Laboratory | Trevaskis Lab, Creek Lab |
| Last Name | Anderson |
| First Name | Dovile |
| Address | 6 Anderson |
| dovile.anderson@gmail.com | |
| Phone | 8671141 |
| Submit Date | 2021-05-12 |
| Num Groups | 3 |
| Total Subjects | 26 |
| Num Males | 26 |
| Publications | Manuscript NATMETAB-A20022406A Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential novel treatment target in obesity |
| Raw Data Available | Yes |
| Raw Data File Type(s) | raw(Thermo) |
| Analysis Type Detail | LC-MS |
| Release Date | 2021-06-02 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR001139 |
| Project DOI: | doi: 10.21228/M8GH59 |
| Project Title: | Changes in mesenteric lymph lipid profile of mice upon high-fat diet with and without Celecoxib |
| Project Type: | Untargeted lipidomics |
| Project Summary: | Untargeted lipidomic profiling of mice mesenteric lymph upon HFD diet and HFD supplemented with COX-2 inhibitor drug Celecoxib. It is proposed that Celecoxib can rescue from negative morphological changes induced by obesity/HFD diet in lymphatic system. |
| Institute: | Monash Institute of Pharmaceutical Sciences |
| Department: | Drug Delivery, Disposition and Dynamics |
| Laboratory: | Trevaskis Lab, Creek Lab |
| Last Name: | Anderson |
| First Name: | Dovile |
| Address: | 399 Royal Pd |
| Email: | dovile.anderson@monash.edu |
| Phone: | +61448671141 |
| Funding Source: | Department of Health | National Health and Medical Research Council (NHMRC) - 1100036 [Trevaskis] |
| Project Comments: | This lipidomics project is part of a larger obesity/lymph research as described in the manuscript |
| Publications: | Manuscript NATMETAB-A20022406A Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential novel treatment target in obesity |
| Contributors: | Dr Enyuan Cao , Matthew Watt , Cameron Nowell , Dr Tim Quach , Jamie Simpson , Ms Violena Ferreira , Sonya Argawal , Hannah Chu , Anubhav Srivastava , Dr Dovile Anderson , Gracia Gracia , Alina Lam , Gabriela Segal , Jiwon Hong , Dr Luojuan Hu , Kian Lium Phang , Alistair Escott , Professor John Windsor , Anthony Phillips , Darren Creek , Professor Natasha Harvey , Professor Christopher Porter |
Subject:
| Subject ID: | SU001872 |
| Subject Type: | Mammal |
| Subject Species: | Mus musculus |
| Taxonomy ID: | 10090 |
| Genotype Strain: | C57BL6/J |
| Age Or Age Range: | 6-7 weeks |
| Gender: | Male |
| Animal Housing: | temperature-controlled room under specific-pathogen free (SPF) or standard animal housing conditions with free access to food and water |
| Animal Feed: | semi-purified normal chow diet (control fat diet (CFD), 7% w/w fat and 16% total energy from fat; AIN93G, Specialty Feeds Pty Ltd, Australia) or high fat diet (HFD, 36% w/w fat and 59% total energy from fat; SF03-002, Specialty Feeds Pty Ltd, Australia) |
| Animal Water: | ad libitum |
Factors:
Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)
| mb_sample_id | local_sample_id | Treatment |
|---|---|---|
| SA167157 | Celecoxib_HFD_3 | Celecoxib_HFD |
| SA167158 | Celecoxib_HFD_9 | Celecoxib_HFD |
| SA167159 | Celecoxib_HFD_2 | Celecoxib_HFD |
| SA167160 | Celecoxib_HFD_5 | Celecoxib_HFD |
| SA167161 | Celecoxib_HFD_4 | Celecoxib_HFD |
| SA167162 | Celecoxib_HFD_8 | Celecoxib_HFD |
| SA167163 | Celecoxib_HFD_1 | Celecoxib_HFD |
| SA167164 | Celecoxib_HFD_7 | Celecoxib_HFD |
| SA167165 | Celecoxib_HFD_6 | Celecoxib_HFD |
| SA167149 | CFD_3 | CFD |
| SA167150 | CFD_2 | CFD |
| SA167151 | CFD_4 | CFD |
| SA167152 | CFD_7 | CFD |
| SA167153 | CFD_8 | CFD |
| SA167154 | CFD_1 | CFD |
| SA167155 | CFD_6 | CFD |
| SA167156 | CFD_5 | CFD |
| SA167166 | HFD_7 | HFD |
| SA167167 | HFD_8 | HFD |
| SA167168 | HFD_9 | HFD |
| SA167169 | HFD_6 | HFD |
| SA167170 | HFD_1 | HFD |
| SA167171 | HFD_2 | HFD |
| SA167172 | HFD_3 | HFD |
| SA167173 | HFD_4 | HFD |
| SA167174 | HFD_5 | HFD |
| Showing results 1 to 26 of 26 |
Collection:
| Collection ID: | CO001865 |
| Collection Summary: | The efferent mesenteric lymphatic duct was cannulated in isoflurane anaesthetised non-fasted mice or rats and lymph fluid was collected for up to 4 h. For the lymphatic drug transport study, lymph was collected in mice that were fasted for 3-4 h. The mesenteric lymph duct cannulation was performed as described previously in rats4 and mice5 and mesenteric lymph fluid was collected continuously for up to 6 h. |
| Sample Type: | Mesenteric lymph |
| Storage Conditions: | -80℃ |
Treatment:
| Treatment ID: | TR001885 |
| Treatment Summary: | Celecoxib was incorporated into HFD feed at a dose equivalent to ~29 mg/kg/day (based on average food intake). Mice were fed for 15 weeks before the analysis. |
Sample Preparation:
| Sampleprep ID: | SP001878 |
| Sampleprep Summary: | For lipidomics analysis, lipid was extracted from mesenteric lymph by chloroform:methanol (1:3). Samples were vortexed for 1 h at 4°C and then centrifuged at 16,000 g for 10 min. Supernatant was carefully transferred to another tube and stored at -80°C until analysis. Before LC-MS analysis, the extract was dried with nitrogen and reconstituted in 20 µl water and 180 µl butanol-methanol (1:1 v/v). The reconstituted extract was vortexed (Vortex mixer, Ratek) for 200 sec with 20 cycles of 5 sec spin and 20 sec vortex. The extract was sonicated in a water bath for 1 hour which was maintained at <20°C by sonicating the samples on ice. The samples were then centrifuged for 10 min at 16,000 g and the supernatant was transferred to LC-MS vials and stored at 4°C prior to analysis. |
| Processing Storage Conditions: | 4℃ |
| Extract Storage: | -80℃ |
Combined analysis:
| Analysis ID | AN002915 | AN002916 |
|---|---|---|
| Analysis type | MS | MS |
| Chromatography type | Reversed phase | Reversed phase |
| Chromatography system | Thermo Dionex Ultimate 3000 RS | Thermo Dionex Ultimate 3000 RS |
| Column | Sigma Aldrich,Supleco,C8 (100 x 2.1mm,2.7um) | Sigma Aldrich,Supleco,C8 (100 x 2.1mm,2.7um) |
| MS Type | ESI | ESI |
| MS instrument type | Orbitrap | Orbitrap |
| MS instrument name | Thermo Q Exactive Orbitrap | Thermo Q Exactive Orbitrap |
| Ion Mode | POSITIVE | NEGATIVE |
| Units | height | height |
Chromatography:
| Chromatography ID: | CH002159 |
| Chromatography Summary: | Lipidomics analysis was performed using reversed phase liquid chromatography and high-resolution mass spectrometry. Samples (10 µl) were injected onto a Dionex Ultimate 3000 UHPLC system (Thermo Scientific, Australia) fitted with an analytical C8 column (100 x 2.1 mm; 2.7 µm, Sigma Aldrich, Australia). Chromatography was performed using solvent A (2 mM formic acid, 8 mM ammonium formate, 40% v/v isopropanol) and solvent B (2 mM formic acid, 8 mM ammonium formate, 98% v/v isopropanol) as mobile phases with a 30 min gradient starting at 0% B and increasing to 35% B from 0 to 8 min, then to 50% B from 8-16 min, then to 80% B from 16-19 min, then finally to 100% B by 23 min. 100% B was maintained for a further 3 min before equilibrating to 0% by 28 min and washing for a further 2 min. |
| Instrument Name: | Thermo Dionex Ultimate 3000 RS |
| Column Name: | Sigma Aldrich,Supleco,C8 (100 x 2.1mm,2.7um) |
| Column Temperature: | 40C |
| Flow Gradient: | 0 min - 0%B, 8 min - 35%B, 16 min - 50%B, 19 min - 80%B, 23 min 100%B, 26 min - 100%B, 28 min - 0%B |
| Flow Rate: | 0.2 ml/min |
| Injection Temperature: | 4 |
| Solvent A: | 40% isopropanol/60% water; 2 mM formic acid; 8 mM ammonium formate, |
| Solvent B: | 98% isopropanol/2% water; 2 mM formic acid; 8 mM ammonium formate |
| Analytical Time: | 30 min |
| Oven Temperature: | 40C |
| Sample Loop Size: | 25 uL |
| Sample Syringe Size: | 25 uL |
| Chromatography Type: | Reversed phase |
MS:
| MS ID: | MS002707 |
| Analysis ID: | AN002915 |
| Instrument Name: | Thermo Q Exactive Orbitrap |
| Instrument Type: | Orbitrap |
| MS Type: | ESI |
| MS Comments: | Pos and neg data were acquired during the same chromatographic run using polarity switching. Full scan acquisition mode, resolution 140k, AGC target 3e6, max IT 200 ms, mass range 140-2000 m/z, number of scans 1 |
| Ion Mode: | POSITIVE |
| Mass Accuracy: | 3 ppm |
| Automatic Gain Control: | 3e6 |
| Desolvation Gas Flow: | 34 |
| Interface Voltage: | 3.5 kV |
| MS ID: | MS002708 |
| Analysis ID: | AN002916 |
| Instrument Name: | Thermo Q Exactive Orbitrap |
| Instrument Type: | Orbitrap |
| MS Type: | ESI |
| MS Comments: | Pos and neg data were acquired during the same chromatographic run using polarity switching. Full scan acquisition mode, resolution 140k, AGC target 3e6, max IT 200 ms, mass range 140-2000 m/z, number of scans 1 |
| Ion Mode: | NEGATIVE |
| Mass Accuracy: | 3 ppm |
| Automatic Gain Control: | 3e6 |
| Desolvation Gas Flow: | 34 |
| Interface Voltage: | 3.5 kV |
